Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May; 4(3):324-31.

View in: PubMed

subject areas

Aged
Angiotensin II Type 1 Receptor Blockers
Biphenyl Compounds
Body Mass Index
Cardiovascular Diseases
Female
Heart Failure
Humans
Male
Middle Aged
Obesity
Prognosis
Stroke Volume
Tetrazoles

authors with profiles

Michael R. Zile